Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-101 for Chronic Antibiotic-resistant Pouchitis (Phase 2/3, 12-week, Randomized, Double-blind, Placebo-controlled)
2020-000048-73Phase 2Unknown
- Sponsor
- Applied Molecular Transport
- Start
- Jun 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pouchitis comparing AMT-101 with Placebo (2 arms). Primary endpoint: Co-primary Efficacy Endpoints. Status: unknown.
02
Drugs
AMT-101
03
Conditions
pouchitis
Beyond the preview
Go deeper on 2020-000048-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000048-73.